Profile: Sierra Oncology Inc (SRRA.OQ)
28 Sep 2020
Sierra Oncology, Inc., incorporated on May 8, 2003, is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Momelotinib, the Company’s lead drug candidate, is a potent, selective and orally-bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor with a differentiated therapeutic profile in myelofibrosis.
The Company is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DDR network. SRA141 is a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).
Sierra Oncology Inc
2150 ? 885 West Georgia Street
VANCOUVER BC V6C 3E8
Company Web Links
- BRIEF-Sierra Oncology Appoints Dr. Stephen Dilly As President And Chief Executive Officer
- BRIEF-Sierra Oncology Reports Q1 Net Loss Per Share Of $3.14
- BRIEF-Sierra Oncology Says Amended Bylaws To Adopt Provision Designating Federal DC's Of U.S. As Exclusive Jurisdiction For Any Litigation Under 1933 Securities Act